197 results on '"Zou, Yiyu"'
Search Results
2. First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer
3. 3189 – ELEVATED CLONAL HEMATOPOIESIS SEEN IN WTC 9/11 FIRST RESPONDERS HAS DISTINCT AGE-RELATED PATTERNS AND RELIES ON IL1RAP FOR CLONAL EXPANSION
4. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
5. Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer
6. Inhibitors of BRAF dimers using an allosteric site
7. Data from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
8. Supplementary Figures 1 - 3 from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
9. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL
10. Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine
11. Data from Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
12. Supplementary Figure 3 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
13. Supplementary Figure Legend from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
14. Supplementary Figure 1 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
15. Supplementary Figure 2 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab
16. 2009 – WORLD TRADE CENTER 9/11 DISASTER EXPOSURE IS ASSOCIATED WITH CLONAL HEMATOPOIESIS IN FIRST RESPONDERS AND IS CHARACTERIZED BY INNATE IMMUNE INFLAMMATION.
17. Antiphospholipid Antibodies Promote Tissue Factor–Dependent Angiogenic Switch and Tumor Progression
18. The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib
19. Intratracheally Administered 5-Azacytidine Is Effective Against Orthotopic Human Lung Cancer Xenograft Models and Devoid of Important Systemic Toxicity
20. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
21. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-β2 expression
22. Epigenetic Control of Tumor Suppressor Genes in Lung Cancer
23. The suppression of colon cancer cell growth in nude mice by targetingβ-catenin/TCF pathway
24. Phase I study of liposomal annamycin
25. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer
26. The effect of a ketogenic diet and synergy with rapamycin in a mouse model of breast cancer
27. Functional succinate dehydrogenase deficiency and loss of ascorbic acid transporter SLC23A1 are pathognomonic adverse features of clear cell renal cancer
28. RICTOR amplification as a novel therapeutic target for lung cancer brain metastases.
29. The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
30. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells
31. Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery
32. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles
33. IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
34. Liposomes as carriers of lipophilic antitumor agents
35. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells
36. Non-Cross-Resistant Anthracyclines with Reduced Basicity and Increased Stability of the Glycosidic Bond
37. Use of Drug Carriers To Ameliorate the Therapeutic Index of Anthracycline Antibiotics
38. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts
39. Abstract 4748: RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) inEGFR-mutated non-small cell lung cancer (NSCLC)
40. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
41. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes
42. TRIB2 contributes to cisplatin resistance in small cell lung cancer
43. Abstract 1170: Notch pathway is overexpressed and is a therapeutic target in clear cell renal cancer
44. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region
45. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
46. RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
47. Role of DNA methylation in renal cell carcinoma
48. Dysregulated Inflammatory Signaling upon Charcot-Marie-Tooth Type 1C Mutation of SIMPLE Protein
49. Aerosol Azacytidine Inhibits Orthotopic Lung Cancers in Mice through Its DNA Demethylation and Gene Reactivation Effects
50. Abstract 589: DNA demethylating agent and histone deacetylation inhibitor synergistically induce paired box 5 gene expression in non-small cell lung cancer cell lines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.